Tenaya Therapeutics and Alnylam Pharmaceuticals announced a research collaboration on March 5, 2026, to identify and validate up to 15 genetic targets for cardiovascular disease treatments14
Tenaya will receive up to $10 million in upfront payments plus research funding reimbursement over a two-year validation term14
Tenaya is eligible to receive up to $1.13 billion in development and commercial milestone payments if all validated targets lead to approved therapeutics14
Alnylam will assume responsibility for all development and commercialization activities of any resulting therapeutics14
The partnership combines Tenaya's expertise in genetic target identification and validation with Alnylam's leadership in RNA interference (RNAi) therapeutics13
Tenaya's existing pipeline includes gene therapies for hypertrophic and arrhythmogenic cardiomyopathies and a small molecule HDAC6 inhibitor3
Tenaya shares rose approximately 10-12% in premarket trading following the announcement24
Sources:
1. https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-br4m7y44cga4.html
2. https://nationaltoday.com/us/ca/south-san-francisco/news/2026/03/05/alnylam-tenaya-announce-1-1b-cardiovascular-drug-pact/
3. https://marketchameleon.com/articles/b/2026/3/5/tenaya-therapeutics-alnylam-collaboration-cardiovascular-innovation
4. https://www.nasdaq.com/articles/tenaya-enters-research-collaboration-alnylam-receive-10-mln-upfront-payments